Login to Your Account

MacroGenics Advancing MAb Program With $45M Series C

By Jennifer Boggs

Thursday, May 18, 2006
Working to finalize the protocol for a potentially pivotal trial of its anti-CD3 antibody for diabetes, MacroGenics Inc. raised $45 million in a Series C round. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription